Current Status of Molecular Targeted Therapies in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death in Korea. Curative treatment is only possible when the disease is diagnosed at the early stage. The prognosis of patients with HCC is even dismal in advanced stages. No systemic cytotoxic chemotherapy has proven to be benefi...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:The Korean journal of gastroenterology Ročník 61; číslo 3; s. 136
Hlavní autori: Suh, Sang Jun, Yim, Hyung Joon
Médium: Journal Article
Jazyk:Korean
Vydavateľské údaje: 25.03.2013
ISSN:1598-9992, 2233-6869, 2233-6869
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Abstract Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death in Korea. Curative treatment is only possible when the disease is diagnosed at the early stage. The prognosis of patients with HCC is even dismal in advanced stages. No systemic cytotoxic chemotherapy has proven to be beneficial in overall survival. Recently, the understanding of the molecular pathogenesis led to the development of new therapies. With the evidence of dysregulation of critical genes associated with cellular proliferation, growth factor signaling, cell cycling, apoptosis, and angiogenesis in HCC, a number of molecular target agents are under clinical trials. Sorafenib is the first systemic anticancer drug which has proven to gain survival benefit in the global as well as Asia-Pacific trials. However, the survival gain is still modest, and further efforts to improve outcomes in patients with HCC are necessary by developing novel drugs or combining other forms of therapies. This article will review signaling pathways in HCC and introduce molecular target agents under investigation currently.Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death in Korea. Curative treatment is only possible when the disease is diagnosed at the early stage. The prognosis of patients with HCC is even dismal in advanced stages. No systemic cytotoxic chemotherapy has proven to be beneficial in overall survival. Recently, the understanding of the molecular pathogenesis led to the development of new therapies. With the evidence of dysregulation of critical genes associated with cellular proliferation, growth factor signaling, cell cycling, apoptosis, and angiogenesis in HCC, a number of molecular target agents are under clinical trials. Sorafenib is the first systemic anticancer drug which has proven to gain survival benefit in the global as well as Asia-Pacific trials. However, the survival gain is still modest, and further efforts to improve outcomes in patients with HCC are necessary by developing novel drugs or combining other forms of therapies. This article will review signaling pathways in HCC and introduce molecular target agents under investigation currently.
AbstractList Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death in Korea. Curative treatment is only possible when the disease is diagnosed at the early stage. The prognosis of patients with HCC is even dismal in advanced stages. No systemic cytotoxic chemotherapy has proven to be beneficial in overall survival. Recently, the understanding of the molecular pathogenesis led to the development of new therapies. With the evidence of dysregulation of critical genes associated with cellular proliferation, growth factor signaling, cell cycling, apoptosis, and angiogenesis in HCC, a number of molecular target agents are under clinical trials. Sorafenib is the first systemic anticancer drug which has proven to gain survival benefit in the global as well as Asia-Pacific trials. However, the survival gain is still modest, and further efforts to improve outcomes in patients with HCC are necessary by developing novel drugs or combining other forms of therapies. This article will review signaling pathways in HCC and introduce molecular target agents under investigation currently.Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death in Korea. Curative treatment is only possible when the disease is diagnosed at the early stage. The prognosis of patients with HCC is even dismal in advanced stages. No systemic cytotoxic chemotherapy has proven to be beneficial in overall survival. Recently, the understanding of the molecular pathogenesis led to the development of new therapies. With the evidence of dysregulation of critical genes associated with cellular proliferation, growth factor signaling, cell cycling, apoptosis, and angiogenesis in HCC, a number of molecular target agents are under clinical trials. Sorafenib is the first systemic anticancer drug which has proven to gain survival benefit in the global as well as Asia-Pacific trials. However, the survival gain is still modest, and further efforts to improve outcomes in patients with HCC are necessary by developing novel drugs or combining other forms of therapies. This article will review signaling pathways in HCC and introduce molecular target agents under investigation currently.
Author Yim, Hyung Joon
Suh, Sang Jun
Author_xml – sequence: 1
  givenname: Sang Jun
  surname: Suh
  fullname: Suh, Sang Jun
  organization: Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea
– sequence: 2
  givenname: Hyung Joon
  surname: Yim
  fullname: Yim, Hyung Joon
  organization: Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea
BookMark eNp9kLFOwzAQQC1UJErpB7BlZEnw2bETjygCCipiIMyW4zjFkMbBdgb-npQyMTCddHrvdHrnaDG4wSB0CTjLgfPrj_ddRjDQjENGM6D8BC0JoTTlJRcLtAQmylQIQc7QOgTb4HkBHDAs0WM1eW-GmLxEFaeQuC55cr3RU698Uiu_M9G0Sf1mvBqtCYkdko0ZVXTa9P0PVCmv7eD26gKddqoPZv07V-j17rauNun2-f6hutmmGgSNacNxTgQIYFSUHS5EV2LNWcMI0bo0TcFErqlqeGtaVnZ53oICYJjkhClSCLpCV8e7o3efkwlR7m04vKMG46YggRJeEJaLYkbhiGrvQvCmk6O3e-W_JGB5SCfndPKQTnKQdFb57BR_HG3nNtYN0Svb_2N-A7hLdXI
CitedBy_id crossref_primary_10_3748_wjg_v21_i13_3826
crossref_primary_10_3892_ol_2015_4048
crossref_primary_10_1016_j_intimp_2015_03_028
Cites_doi 10.1200/JCO.2005.14.696
10.1158/1078-0432.CCR-11-0793
10.1517/14656566.2012.679930
10.1586/14737140.9.2.247
10.1002/cncr.26165
10.1007/s00280-011-1753-2
10.1016/j.jhep.2008.12.011
10.1038/sj.bjc.6605017
10.1007/s00280-009-0927-7
10.1002/cncr.22886
10.3748/wjg.v18.i42.6005
10.1111/j.1478-3231.2004.0940.x
10.1158/1078-0432.CCR-09-0465
10.1200/JCO.2008.20.0931
10.1056/NEJMra0707704
10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R
10.1002/hep.25637
10.1186/1471-230X-3-19
10.1038/nrd2530
10.1001/jama.2010.1672
10.1016/j.jhep.2011.12.013
10.1200/JCO.2005.04.9130
10.1016/S1470-2045(08)70285-7
10.1007/BF02934089
10.1309/LQ9EMK8QKE75NGGX
10.1016/S0016-5085(97)70158-6
10.1200/JCO.2008.18.3301
10.1200/jco.2011.29.15_suppl.4043
10.1053/j.gastro.2006.01.006
10.1074/jbc.M101056200
10.1177/002215549704500710
10.1111/j.1349-7006.2007.00648.x
10.1038/sj.onc.1210422
10.1158/1535-7163.MCT-06-0720
10.1200/JCO.2010.33.9432
10.1016/j.cytogfr.2004.03.005
10.1371/journal.pone.0036713
10.1002/hep.24644
10.1111/j.1582-4934.2008.00364.x
10.1634/theoncologist.2011-0253
10.1200/JCO.2005.01.3441
10.1055/s-2004-814151
10.1016/j.jhep.2010.01.035
10.1002/(SICI)1097-0045(199611)29:5<282::AID-PROS2>3.0.CO;2-C
10.1200/jco.2007.25.18_suppl.3505
10.4155/fmc.09.89
10.1152/physrev.1999.79.4.1283
10.1634/theoncologist.2009-0143
10.1158/0008-5472.CAN-06-1377
10.1056/NEJMoa0708857
10.1002/hep.510270409
10.1593/neo.09476
10.1038/nrc2664
10.1016/j.ejca.2011.12.006
10.1309/WF10QAAED3PP93BH
10.1002/cncr.23489
10.1210/er.18.1.4
10.1007/s11605-007-0396-4
10.1158/1078-0432.CCR-10-2011
10.1126/science.1079666
10.1073/pnas.0409722102
10.1200/JCO.2007.15.9947
10.1016/j.jhep.2012.02.016
10.1002/cncr.27758
10.1006/gyno.1998.5121
10.1016/S1470-2045(09)70171-8
10.1002/hep.22506
10.1111/j.1365-2036.2010.04404.x
10.1200/jco.2011.29.15_suppl.4001
10.1006/bbrc.1997.6840
10.1007/s10637-012-9808-8
10.1038/sj.onc.1206160
10.1016/S0168-8278(12)61409-3
10.1038/sj.onc.1210623
10.1159/000335963
10.5414/CPP42650
10.1124/jpet.110.175786
ContentType Journal Article
DBID AAYXX
CITATION
7X8
DOI 10.4166/kjg.2013.61.3.136
DatabaseName CrossRef
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
Database_xml – sequence: 1
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
EISSN 2233-6869
ExternalDocumentID 10_4166_kjg_2013_61_3_136
GroupedDBID 5-W
8JR
8XY
AAYXX
ADBBV
ALMA_UNASSIGNED_HOLDINGS
BCNDV
CITATION
EBD
EF.
EMOBN
F5P
GROUPED_DOAJ
OK1
SV3
7X8
ID FETCH-LOGICAL-c193t-b604291915398f079f80c65b522cc8eb7594c3ab6ded58f44d1a11502425a2793
ISSN 1598-9992
2233-6869
IngestDate Fri Jul 11 07:40:11 EDT 2025
Sat Nov 29 03:32:16 EST 2025
Tue Nov 18 20:51:31 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 3
Language Korean
License http://creativecommons.org/licenses/by-nc/3.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c193t-b604291915398f079f80c65b522cc8eb7594c3ab6ded58f44d1a11502425a2793
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
PQID 1326725497
PQPubID 23479
ParticipantIDs proquest_miscellaneous_1326725497
crossref_primary_10_4166_kjg_2013_61_3_136
crossref_citationtrail_10_4166_kjg_2013_61_3_136
PublicationCentury 2000
PublicationDate 2013-03-25
PublicationDateYYYYMMDD 2013-03-25
PublicationDate_xml – month: 03
  year: 2013
  text: 2013-03-25
  day: 25
PublicationDecade 2010
PublicationTitle The Korean journal of gastroenterology
PublicationYear 2013
References Engelman (10.4166/kjg.2013.61.3.136_ref10) 2009; 9
French (10.4166/kjg.2013.61.3.136_ref32) 2012; 7
Kaseb (10.4166/kjg.2013.61.3.136_ref81) 2012; 82
Campbell (10.4166/kjg.2013.61.3.136_ref28) 2005; 102
Buckley (10.4166/kjg.2013.61.3.136_ref13) 2008; 129
Bekaii-Saab (10.4166/kjg.2013.61.3.136_ref67) 2009; 15
Llovet (10.4166/kjg.2013.61.3.136_ref59) 2012; 56
Kudo (10.4166/kjg.2013.61.3.136_ref2) 2012; 18
Philip (10.4166/kjg.2013.61.3.136_ref64) 2005; 23
Ito (10.4166/kjg.2013.61.3.136_ref8) 1998; 27
Desnoyers (10.4166/kjg.2013.61.3.136_ref31) 2008; 27
Ferrara (10.4166/kjg.2013.61.3.136_ref14) 1997; 18
Chen (10.4166/kjg.2013.61.3.136_ref51) 2011; 337
Clarke (10.4166/kjg.2013.61.3.136_ref21) 2003; 22
Hughes (10.4166/kjg.2013.61.3.136_ref30) 1997; 45
Abou-Alfa (10.4166/kjg.2013.61.3.136_ref40) 2006; 24
Faivre (10.4166/kjg.2013.61.3.136_ref63) 2009; 10
Faivre (10.4166/kjg.2013.61.3.136_ref74) 2010; 52
Wong (10.4166/kjg.2013.61.3.136_ref35) 2001; 92
Heldin (10.4166/kjg.2013.61.3.136_ref19) 1999; 79
Fernández (10.4166/kjg.2013.61.3.136_ref16) 2009; 50
Vincenzi (10.4166/kjg.2013.61.3.136_ref47) 2010; 15
Yau (10.4166/kjg.2013.61.3.136_ref62) 2011; 17
Chen (10.4166/kjg.2013.61.3.136_ref34) 2009; 11
Woo (10.4166/kjg.2013.61.3.136_ref37) 2012; 13
Gilbertson (10.4166/kjg.2013.61.3.136_ref27) 2001; 276
Bettinger (10.4166/kjg.2013.61.3.136_ref48) 2012; 56
Toh (10.4166/kjg.2013.61.3.136_ref60) 2013; 119
Asnacios (10.4166/kjg.2013.61.3.136_ref70) 2008; 112
Marrero (10.4166/kjg.2013.61.3.136_ref44) 2011; 29
Betsholtz (10.4166/kjg.2013.61.3.136_ref18) 2004; 15
Higano (10.4166/kjg.2013.61.3.136_ref72) 2007; 25
Stock (10.4166/kjg.2013.61.3.136_ref29) 2007; 6
Treiber (10.4166/kjg.2013.61.3.136_ref52) 2009; 9
Calvisi (10.4166/kjg.2013.61.3.136_ref6) 2006; 130
Siegel (10.4166/kjg.2013.61.3.136_ref56) 2008; 26
Comoglio (10.4166/kjg.2013.61.3.136_ref11) 2008; 7
Furuse (10.4166/kjg.2013.61.3.136_ref38) 2008; 99
Richly (10.4166/kjg.2013.61.3.136_ref76) 2004; 42
Park (10.4166/kjg.2013.61.3.136_ref57) 2011; 17
Friedman (10.4166/kjg.2013.61.3.136_ref25) 1997; 112
Chiorean (10.4166/kjg.2013.61.3.136_ref71) 2012; 17
Miller (10.4166/kjg.2013.61.3.136_ref39) 2009; 27
Bruix (10.4166/kjg.2013.61.3.136_ref42) 2009; 27
Scharf (10.4166/kjg.2013.61.3.136_ref33) 2003; 35
Thomas (10.4166/kjg.2013.61.3.136_ref68) 2009; 27
Personeni (10.4166/kjg.2013.61.3.136_ref46) 2012; 57
Zhu (10.4166/kjg.2013.61.3.136_ref80) 2006; 24
Schöniger-Hekele (10.4166/kjg.2013.61.3.136_ref53) 2010; 32
Sulzbacher (10.4166/kjg.2013.61.3.136_ref24) 2003; 120
Thomas (10.4166/kjg.2013.61.3.136_ref65) 2007; 110
Llovet (10.4166/kjg.2013.61.3.136_ref3) 2008; 48
Huynh (10.4166/kjg.2013.61.3.136_ref54) 2009; 13
Ikura (10.4166/kjg.2013.61.3.136_ref26) 1997; 32
Schoenleber (10.4166/kjg.2013.61.3.136_ref17) 2009; 100
Heinrich (10.4166/kjg.2013.61.3.136_ref20) 2003; 299
Mulvihill (10.4166/kjg.2013.61.3.136_ref75) 2009; 1
Abou-Alfa (10.4166/kjg.2013.61.3.136_ref77) 2010; 304
Fudge (10.4166/kjg.2013.61.3.136_ref23) 1996; 29
Cheng (10.4166/kjg.2013.61.3.136_ref43) 2012; 48
Wentz (10.4166/kjg.2013.61.3.136_ref49) 2008; 12
Abou-Alfa (10.4166/kjg.2013.61.3.136_ref73) 2011; 29
Schmidt (10.4166/kjg.2013.61.3.136_ref5) 1997; 236
Griffioen (10.4166/kjg.2013.61.3.136_ref15) 2000; 52
Iavarone (10.4166/kjg.2013.61.3.136_ref45) 2011; 54
Johnson (10.4166/kjg.2013.61.3.136_ref58) 2012; 56
Dabrow (10.4166/kjg.2013.61.3.136_ref22) 1998; 71
Tsuboi (10.4166/kjg.2013.61.3.136_ref9) 2004; 24
Hsu (10.4166/kjg.2013.61.3.136_ref61) 2012; 56
Roberts (10.4166/kjg.2013.61.3.136_ref4) 2007; 26
Huynh (10.4166/kjg.2013.61.3.136_ref7) 2003; 3
Zhu (10.4166/kjg.2013.61.3.136_ref55) 2011; 117
Yau (10.4166/kjg.2013.61.3.136_ref69) 2012; 30
Petrini (10.4166/kjg.2013.61.3.136_ref78) 2012; 69
Ciardiello (10.4166/kjg.2013.61.3.136_ref12) 2008; 358
Cheng (10.4166/kjg.2013.61.3.136_ref41) 2009; 10
Llovet (10.4166/kjg.2013.61.3.136_ref1) 2008; 359
Ramanathan (10.4166/kjg.2013.61.3.136_ref66) 2009; 64
Hsu (10.4166/kjg.2013.61.3.136_ref79) 2010; 53
O'Neil (10.4166/kjg.2013.61.3.136_ref50) 2011; 29
Liu (10.4166/kjg.2013.61.3.136_ref36) 2006; 66
References_xml – volume: 23
  start-page: 6657
  year: 2005
  ident: 10.4166/kjg.2013.61.3.136_ref64
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2005.14.696
– volume: 17
  start-page: 6914
  year: 2011
  ident: 10.4166/kjg.2013.61.3.136_ref62
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-11-0793
– volume: 13
  start-page: 1059
  year: 2012
  ident: 10.4166/kjg.2013.61.3.136_ref37
  publication-title: Expert Opin Pharmacother
  doi: 10.1517/14656566.2012.679930
– volume: 9
  start-page: 247
  year: 2009
  ident: 10.4166/kjg.2013.61.3.136_ref52
  publication-title: Expert Rev Anticancer Ther
  doi: 10.1586/14737140.9.2.247
– volume: 117
  start-page: 5094
  year: 2011
  ident: 10.4166/kjg.2013.61.3.136_ref55
  publication-title: Cancer
  doi: 10.1002/cncr.26165
– volume: 69
  start-page: 773
  year: 2012
  ident: 10.4166/kjg.2013.61.3.136_ref78
  publication-title: Cancer Chemother Pharmacol
  doi: 10.1007/s00280-011-1753-2
– volume: 50
  start-page: 604
  year: 2009
  ident: 10.4166/kjg.2013.61.3.136_ref16
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2008.12.011
– volume: 100
  start-page: 1385
  year: 2009
  ident: 10.4166/kjg.2013.61.3.136_ref17
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6605017
– volume: 64
  start-page: 777
  year: 2009
  ident: 10.4166/kjg.2013.61.3.136_ref66
  publication-title: Cancer Chemother Pharmacol
  doi: 10.1007/s00280-009-0927-7
– volume: 56
  start-page: 1519A
  issue: Suppl
  year: 2012
  ident: 10.4166/kjg.2013.61.3.136_ref58
  publication-title: Hepatology
– volume: 110
  start-page: 1059
  year: 2007
  ident: 10.4166/kjg.2013.61.3.136_ref65
  publication-title: Cancer
  doi: 10.1002/cncr.22886
– volume: 18
  start-page: 6005
  year: 2012
  ident: 10.4166/kjg.2013.61.3.136_ref2
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.v18.i42.6005
– volume: 24
  start-page: 432
  year: 2004
  ident: 10.4166/kjg.2013.61.3.136_ref9
  publication-title: Liver Int
  doi: 10.1111/j.1478-3231.2004.0940.x
– volume: 15
  start-page: 5895
  year: 2009
  ident: 10.4166/kjg.2013.61.3.136_ref67
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-09-0465
– volume: 27
  start-page: 1800
  year: 2009
  ident: 10.4166/kjg.2013.61.3.136_ref39
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.20.0931
– volume: 358
  start-page: 1160
  year: 2008
  ident: 10.4166/kjg.2013.61.3.136_ref12
  publication-title: N Engl J Med
  doi: 10.1056/NEJMra0707704
– volume: 92
  start-page: 136
  year: 2001
  ident: 10.4166/kjg.2013.61.3.136_ref35
  publication-title: Cancer
  doi: 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R
– volume: 56
  start-page: 789
  year: 2012
  ident: 10.4166/kjg.2013.61.3.136_ref48
  publication-title: Hepatology
  doi: 10.1002/hep.25637
– volume: 3
  start-page: 19
  year: 2003
  ident: 10.4166/kjg.2013.61.3.136_ref7
  publication-title: BMC Gastroenterol
  doi: 10.1186/1471-230X-3-19
– volume: 7
  start-page: 504
  year: 2008
  ident: 10.4166/kjg.2013.61.3.136_ref11
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd2530
– volume: 304
  start-page: 2154
  year: 2010
  ident: 10.4166/kjg.2013.61.3.136_ref77
  publication-title: JAMA
  doi: 10.1001/jama.2010.1672
– volume: 56
  start-page: 1097
  year: 2012
  ident: 10.4166/kjg.2013.61.3.136_ref61
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2011.12.013
– volume: 24
  start-page: 1898
  year: 2006
  ident: 10.4166/kjg.2013.61.3.136_ref80
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2005.04.9130
– volume: 10
  start-page: 25
  year: 2009
  ident: 10.4166/kjg.2013.61.3.136_ref41
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(08)70285-7
– volume: 32
  start-page: 496
  year: 1997
  ident: 10.4166/kjg.2013.61.3.136_ref26
  publication-title: J Gastroenterol
  doi: 10.1007/BF02934089
– volume: 120
  start-page: 107
  year: 2003
  ident: 10.4166/kjg.2013.61.3.136_ref24
  publication-title: Am J Clin Pathol
  doi: 10.1309/LQ9EMK8QKE75NGGX
– volume: 112
  start-page: 1406
  year: 1997
  ident: 10.4166/kjg.2013.61.3.136_ref25
  publication-title: Gastroenterology
  doi: 10.1016/S0016-5085(97)70158-6
– volume: 27
  start-page: 843
  year: 2009
  ident: 10.4166/kjg.2013.61.3.136_ref68
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.18.3301
– volume: 29
  start-page: abstr 4043
  issue: Suppl
  year: 2011
  ident: 10.4166/kjg.2013.61.3.136_ref73
  publication-title: J Clin Oncol
  doi: 10.1200/jco.2011.29.15_suppl.4043
– volume: 130
  start-page: 1117
  year: 2006
  ident: 10.4166/kjg.2013.61.3.136_ref6
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2006.01.006
– volume: 276
  start-page: 27406
  year: 2001
  ident: 10.4166/kjg.2013.61.3.136_ref27
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M101056200
– volume: 45
  start-page: 1005
  year: 1997
  ident: 10.4166/kjg.2013.61.3.136_ref30
  publication-title: J Histochem Cytochem
  doi: 10.1177/002215549704500710
– volume: 99
  start-page: 159
  year: 2008
  ident: 10.4166/kjg.2013.61.3.136_ref38
  publication-title: Cancer Sci
  doi: 10.1111/j.1349-7006.2007.00648.x
– volume: 26
  start-page: 3291
  year: 2007
  ident: 10.4166/kjg.2013.61.3.136_ref4
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1210422
– volume: 6
  start-page: 1932
  year: 2007
  ident: 10.4166/kjg.2013.61.3.136_ref29
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-06-0720
– volume: 29
  start-page: 2350
  year: 2011
  ident: 10.4166/kjg.2013.61.3.136_ref50
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2010.33.9432
– volume: 15
  start-page: 215
  year: 2004
  ident: 10.4166/kjg.2013.61.3.136_ref18
  publication-title: Cytokine Growth Factor Rev
  doi: 10.1016/j.cytogfr.2004.03.005
– volume: 7
  start-page: e36713
  year: 2012
  ident: 10.4166/kjg.2013.61.3.136_ref32
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0036713
– volume: 54
  start-page: 2055
  year: 2011
  ident: 10.4166/kjg.2013.61.3.136_ref45
  publication-title: Hepatology
  doi: 10.1002/hep.24644
– volume: 13
  start-page: 1371
  year: 2009
  ident: 10.4166/kjg.2013.61.3.136_ref54
  publication-title: J Cell Mol Med
  doi: 10.1111/j.1582-4934.2008.00364.x
– volume: 17
  start-page: 13-e26
  year: 2012
  ident: 10.4166/kjg.2013.61.3.136_ref71
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2011-0253
– volume: 24
  start-page: 4293
  year: 2006
  ident: 10.4166/kjg.2013.61.3.136_ref40
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2005.01.3441
– volume: 35
  start-page: 685
  year: 2003
  ident: 10.4166/kjg.2013.61.3.136_ref33
  publication-title: Horm Metab Res
  doi: 10.1055/s-2004-814151
– volume: 53
  start-page: 126
  year: 2010
  ident: 10.4166/kjg.2013.61.3.136_ref79
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2010.01.035
– volume: 29
  start-page: 282
  year: 1996
  ident: 10.4166/kjg.2013.61.3.136_ref23
  publication-title: Prostate
  doi: 10.1002/(SICI)1097-0045(199611)29:5<282::AID-PROS2>3.0.CO;2-C
– volume: 25
  start-page: abstr 3505
  issue: 18 Suppl
  year: 2007
  ident: 10.4166/kjg.2013.61.3.136_ref72
  publication-title: J Clin Oncol
  doi: 10.1200/jco.2007.25.18_suppl.3505
– volume: 1
  start-page: 1153
  year: 2009
  ident: 10.4166/kjg.2013.61.3.136_ref75
  publication-title: Future Med Chem
  doi: 10.4155/fmc.09.89
– volume: 79
  start-page: 1283
  year: 1999
  ident: 10.4166/kjg.2013.61.3.136_ref19
  publication-title: Physiol Rev
  doi: 10.1152/physrev.1999.79.4.1283
– volume: 15
  start-page: 85
  year: 2010
  ident: 10.4166/kjg.2013.61.3.136_ref47
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2009-0143
– volume: 66
  start-page: 11851
  year: 2006
  ident: 10.4166/kjg.2013.61.3.136_ref36
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-06-1377
– volume: 359
  start-page: 378
  year: 2008
  ident: 10.4166/kjg.2013.61.3.136_ref1
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0708857
– volume: 27
  start-page: 951
  year: 1998
  ident: 10.4166/kjg.2013.61.3.136_ref8
  publication-title: Hepatology
  doi: 10.1002/hep.510270409
– volume: 11
  start-page: 835
  year: 2009
  ident: 10.4166/kjg.2013.61.3.136_ref34
  publication-title: Neoplasia
  doi: 10.1593/neo.09476
– volume: 9
  start-page: 550
  year: 2009
  ident: 10.4166/kjg.2013.61.3.136_ref10
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc2664
– volume: 48
  start-page: 1452
  year: 2012
  ident: 10.4166/kjg.2013.61.3.136_ref43
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2011.12.006
– volume: 129
  start-page: 245
  year: 2008
  ident: 10.4166/kjg.2013.61.3.136_ref13
  publication-title: Am J Clin Pathol
  doi: 10.1309/WF10QAAED3PP93BH
– volume: 112
  start-page: 2733
  year: 2008
  ident: 10.4166/kjg.2013.61.3.136_ref70
  publication-title: Cancer
  doi: 10.1002/cncr.23489
– volume: 18
  start-page: 4
  year: 1997
  ident: 10.4166/kjg.2013.61.3.136_ref14
  publication-title: Endocr Rev
  doi: 10.1210/er.18.1.4
– volume: 12
  start-page: 30
  year: 2008
  ident: 10.4166/kjg.2013.61.3.136_ref49
  publication-title: J Gastrointest Surg
  doi: 10.1007/s11605-007-0396-4
– volume: 17
  start-page: 1973
  year: 2011
  ident: 10.4166/kjg.2013.61.3.136_ref57
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-10-2011
– volume: 299
  start-page: 708
  year: 2003
  ident: 10.4166/kjg.2013.61.3.136_ref20
  publication-title: Science
  doi: 10.1126/science.1079666
– volume: 102
  start-page: 3389
  year: 2005
  ident: 10.4166/kjg.2013.61.3.136_ref28
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.0409722102
– volume: 26
  start-page: 2992
  year: 2008
  ident: 10.4166/kjg.2013.61.3.136_ref56
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2007.15.9947
– volume: 57
  start-page: 101
  year: 2012
  ident: 10.4166/kjg.2013.61.3.136_ref46
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2012.02.016
– volume: 119
  start-page: 380
  year: 2013
  ident: 10.4166/kjg.2013.61.3.136_ref60
  publication-title: Cancer
  doi: 10.1002/cncr.27758
– volume: 71
  start-page: 29
  year: 1998
  ident: 10.4166/kjg.2013.61.3.136_ref22
  publication-title: Gynecol Oncol
  doi: 10.1006/gyno.1998.5121
– volume: 27
  start-page: 521s
  issue: 15 Suppl
  year: 2009
  ident: 10.4166/kjg.2013.61.3.136_ref42
  publication-title: J Clin Oncol
– volume: 10
  start-page: 794
  year: 2009
  ident: 10.4166/kjg.2013.61.3.136_ref63
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(09)70171-8
– volume: 48
  start-page: 1312
  year: 2008
  ident: 10.4166/kjg.2013.61.3.136_ref3
  publication-title: Hepatology
  doi: 10.1002/hep.22506
– volume: 32
  start-page: 763
  year: 2010
  ident: 10.4166/kjg.2013.61.3.136_ref53
  publication-title: Aliment Pharmacol Ther
  doi: 10.1111/j.1365-2036.2010.04404.x
– volume: 29
  start-page: abstr 4001
  issue: Suppl
  year: 2011
  ident: 10.4166/kjg.2013.61.3.136_ref44
  publication-title: J Clin Oncol
  doi: 10.1200/jco.2011.29.15_suppl.4001
– volume: 236
  start-page: 54
  year: 1997
  ident: 10.4166/kjg.2013.61.3.136_ref5
  publication-title: Biochem Biophys Res Commun
  doi: 10.1006/bbrc.1997.6840
– volume: 30
  start-page: 2384
  year: 2012
  ident: 10.4166/kjg.2013.61.3.136_ref69
  publication-title: Invest New Drugs
  doi: 10.1007/s10637-012-9808-8
– volume: 22
  start-page: 722
  year: 2003
  ident: 10.4166/kjg.2013.61.3.136_ref21
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1206160
– volume: 56
  start-page: S549
  issue: Suppl 2
  year: 2012
  ident: 10.4166/kjg.2013.61.3.136_ref59
  publication-title: J Hepatol
  doi: 10.1016/S0168-8278(12)61409-3
– volume: 27
  start-page: 85
  year: 2008
  ident: 10.4166/kjg.2013.61.3.136_ref31
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1210623
– volume: 52
  start-page: abstr 288
  issue: Suppl
  year: 2010
  ident: 10.4166/kjg.2013.61.3.136_ref74
  publication-title: Hepatology
– volume: 82
  start-page: 67
  year: 2012
  ident: 10.4166/kjg.2013.61.3.136_ref81
  publication-title: Oncology
  doi: 10.1159/000335963
– volume: 42
  start-page: 650
  year: 2004
  ident: 10.4166/kjg.2013.61.3.136_ref76
  publication-title: Int J Clin Pharmacol Ther
  doi: 10.5414/CPP42650
– volume: 52
  start-page: 237
  year: 2000
  ident: 10.4166/kjg.2013.61.3.136_ref15
  publication-title: Pharmacol Rev
– volume: 337
  start-page: 155
  year: 2011
  ident: 10.4166/kjg.2013.61.3.136_ref51
  publication-title: J Pharmacol Exp Ther
  doi: 10.1124/jpet.110.175786
SSID ssib015916101
ssib003110202
ssib059854591
ssj0064443
Score 1.9196138
SecondaryResourceType review_article
Snippet Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death in Korea. Curative treatment is only possible when the disease is diagnosed at the...
SourceID proquest
crossref
SourceType Aggregation Database
Enrichment Source
Index Database
StartPage 136
Title Current Status of Molecular Targeted Therapies in Hepatocellular Carcinoma
URI https://www.proquest.com/docview/1326725497
Volume 61
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2233-6869
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0064443
  issn: 1598-9992
  databaseCode: DOA
  dateStart: 19680101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2233-6869
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssib059854591
  issn: 1598-9992
  databaseCode: M~E
  dateStart: 19680101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF7RwoFLRQWI8ogWiROVg52193FEVVHVQoVEkMLJ8voR0lZ25MRVufS3d2Z3vamLQPTAxYnW9jje-TT7zWR2hpB3qiplFEod8KRMglixLNATpoKoCrNK6Aw-TXX9z-L0VM5m6qtLyFyZdgKiruXVlVr-V1XDGCgbt87eQ91eKAzAd1A6HEHtcPwnxfcVl5BGdjbFpW-Buz81ed_AMadm29XCZGPB0rME1xtD-OaiA2wvVDfOYJ9t4HTStH3c3nHYebZatw2W9WwH4flv3U8bbq7n-8edx98P27r56FeH441DhIs5YP8HFtj9yb2ZVGAmle1iNy7NGPAMFnBpG6_0ttUWWncYYrcMZWTLntw14EAPMZZwfjbHrDs25tGYjd21w2LZdxYxn1oITg0KSUFEiiJSHqUsBRFb5OFEJAot35frw1s2DSjWpgQavBlw4NDbPHhR4JjKpw0BfbSbNvoZsP-U4yM__Parh1xnuNQb_jJ9Qnac40E_WsDskgfnzVNy7MBCLVhoU1EPFtqDhXqw0EVNh2ChHizPyPdPh9ODo8B11whyIO3rQHPkIuCuJ0zJKhSqkmHOEw2EPM9lqWGu4pxlmhdlkcgqjosoQ_cBfdRsAmb9Odmum7p8QWgBnBDOFXhLDIRHAafmmuUx0mVR6j0S9vOQ5q70PHZAuUj_qK098t7fsrR1V_528dt-clOwjjgFWV023QpOTrjAGIh4eR-Br8jjDexfk-1125VvyKP8cr1YtSOyJWZyZKI3IwOmG28_gfw
linkProvider ISSN International Centre
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Current+Status+of+Molecular+Targeted+Therapies+in+Hepatocellular+Carcinoma&rft.jtitle=The+Korean+journal+of+gastroenterology&rft.au=Suh%2C+Sang+Jun&rft.au=Yim%2C+Hyung+Joon&rft.date=2013-03-25&rft.issn=1598-9992&rft.eissn=2233-6869&rft.volume=61&rft.issue=3&rft.spage=136&rft_id=info:doi/10.4166%2Fkjg.2013.61.3.136&rft.externalDBID=n%2Fa&rft.externalDocID=10_4166_kjg_2013_61_3_136
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1598-9992&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1598-9992&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1598-9992&client=summon